These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 10331691

  • 1. Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b.
    Borràs C, Río J, Porcel J, Barrios M, Tintoré M, Montalban X.
    Neurology; 1999 May 12; 52(8):1636-9. PubMed ID: 10331691
    [Abstract] [Full Text] [Related]

  • 2. Long-term emotional state of multiple sclerosis patients treated with interferon beta.
    Porcel J, Río J, Sánchez-Betancourt A, Arévalo MJ, Tintoré M, Téllez N, Borràs C, Nos C, Montalbán X.
    Mult Scler; 2006 Dec 12; 12(6):802-7. PubMed ID: 17263010
    [Abstract] [Full Text] [Related]

  • 3. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
    Río J, Tintoré M, Nos C, Téllez N, Galán I, Montalban X.
    J Neurol; 2005 Jul 12; 252(7):795-800. PubMed ID: 15772741
    [Abstract] [Full Text] [Related]

  • 4. Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial.
    Patten SB, Metz LM.
    Mult Scler; 2001 Aug 12; 7(4):243-8. PubMed ID: 11548984
    [Abstract] [Full Text] [Related]

  • 5. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B, Jacobs LD.
    Drugs; 2000 Mar 12; 59(3):401-10. PubMed ID: 10776827
    [Abstract] [Full Text] [Related]

  • 6. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S, Rahimi R, Abdollahi M.
    Clin Ther; 2010 Oct 12; 32(11):1871-88. PubMed ID: 21095482
    [Abstract] [Full Text] [Related]

  • 7. Interferon beta-1b treatment modulates TNFalpha and IFNgamma spontaneous gene expression in MS.
    Gayo A, Mozo L, Suárez A, Tuñón A, Lahoz C, Gutiérrez C.
    Neurology; 1999 Jun 10; 52(9):1764-70. PubMed ID: 10371521
    [Abstract] [Full Text] [Related]

  • 8. Urinary myelin basic protein-like material in patients with multiple sclerosis during interferon beta-1b treatment.
    Whitaker JN, Layton BA, Bartolucci AA, Mitchell GW, Bashir K, Goodwin J, Kachelhofer RD.
    Arch Neurol; 1999 Jun 10; 56(6):687-91. PubMed ID: 10369307
    [Abstract] [Full Text] [Related]

  • 9. Multiple sclerosis and depression: influence of interferon beta therapy.
    Zephir H, De Seze J, Stojkovic T, Delisse B, Ferriby D, Cabaret M, Vermersch P.
    Mult Scler; 2003 Jun 10; 9(3):284-8. PubMed ID: 12814176
    [Abstract] [Full Text] [Related]

  • 10. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP.
    Mult Scler; 2001 Dec 10; 7(6):349-53. PubMed ID: 11795454
    [Abstract] [Full Text] [Related]

  • 11. Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS.
    Río J, Nos C, Marzo ME, Tintoré M, Montalban X.
    Neurology; 1998 Jun 10; 50(6):1910-2. PubMed ID: 9633761
    [Abstract] [Full Text] [Related]

  • 12. Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?
    van Boxel-Dezaire AH, van Trigt-Hoff SC, Killestein J, Schrijver HM, van Houwelingen JC, Polman CH, Nagelkerken L.
    Ann Neurol; 2000 Sep 10; 48(3):313-22. PubMed ID: 10976637
    [Abstract] [Full Text] [Related]

  • 13. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS.
    Kracke A, von Wussow P, Al-Masri AN, Dalley G, Windhagen A, Heidenreich F.
    Neurology; 2000 Jan 11; 54(1):193-9. PubMed ID: 10636147
    [Abstract] [Full Text] [Related]

  • 14. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
    Petkau J, White R.
    Mult Scler; 1997 Dec 11; 3(6):402. PubMed ID: 9493643
    [No Abstract] [Full Text] [Related]

  • 15. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
    Barbero P, Bergui M, Versino E, Ricci A, Zhong JJ, Ferrero B, Clerico M, Pipieri A, Verdun E, Giordano L, Durelli L, INCOMIN Trial Study Group.
    Mult Scler; 2006 Feb 11; 12(1):72-6. PubMed ID: 16459722
    [Abstract] [Full Text] [Related]

  • 16. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference.
    Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BG, Burks JS.
    Neurology; 1996 Jan 11; 46(1):12-8. PubMed ID: 8559358
    [Abstract] [Full Text] [Related]

  • 17. MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b.
    Richert ND, Zierak MC, Bash CN, Lewis BK, McFarland HF, Frank JA.
    Mult Scler; 2000 Apr 11; 6(2):86-90. PubMed ID: 10773853
    [Abstract] [Full Text] [Related]

  • 18. Side effect profile of interferon beta-1b in MS: results of an open label trial.
    Neilley LK, Goodin DS, Goodkin DE, Hauser SL.
    Neurology; 1996 Feb 11; 46(2):552-4. PubMed ID: 8614531
    [Abstract] [Full Text] [Related]

  • 19. Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group.
    Zhao GJ, Koopmans RA, Li DK, Bedell L, Paty DW.
    Neurology; 2000 Jan 11; 54(1):200-6. PubMed ID: 10636148
    [Abstract] [Full Text] [Related]

  • 20. History of modern multiple sclerosis therapy.
    Lublin F.
    J Neurol; 2005 Sep 11; 252 Suppl 3():iii3-iii9. PubMed ID: 16170498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.